Distribution pattern and functional state of α1-antichymotrypsin in plaques and vascular amyloid in Alzheimer's disease - An immunohistochemical study with monoclonal antibodies against native and inactivated α1-antichymotrypsin

J. M. Rozemuller, J. J. Abbink, A. M. Kamp, F. C. Stam, C. E. Hack, P. Eikelenboom

Research output: Contribution to journalArticleAcademicpeer-review

90 Citations (Scopus)


Monoclonal antibodies (mAbs) were raised against inactivated α1-antichymotrypsin (ACT) to study the presence and functional state of the serine protease inhibitor α1-antichymotrypsin in cerebral amyloid deposits in Alzheimer's disease. A panel of seven different mAbs was obtained; six of them were directed against neoepitopes that are expressed on ACT after interaction with proteases (inactivated ACT) and one mAb was directed against an epitope that is exposed both on native and inactivated ACT. The mAbs against neoepitopes could discriminate native ACT from complexed and inactivated ACT in vitro as shown in binding experiments in the presence of either native or inactivated ACT. With the mAbs against ACT we found that: (a) besides classical congophilic plaques, amorphous noncongophilic β/A4-positive plaques were stained; (b) amorphous and classical plaques reacted with both types of mAbs against ACT indicating that this ACT was either complexed to a protease or proteolytically inactivated; (c) vascular amyloid was not stained for ACT. The presence of ACT in amorphous and classical plaques and its absence in vascular amyloid may indicate differences in the proteolytic degradation of preamyloid into amyloid fibrils. Our study strongly suggests that ACT is biologically active in amyloid plaques from an early stage.

Original languageEnglish
Pages (from-to)200-207
Number of pages8
JournalActa Neuropathologica
Issue number3
Publication statusPublished - 1 Aug 1991


  • Acute-phase protein
  • Alzheimer's disease
  • Cerebral amyloid
  • Protease inhibitor
  • α1-Antichymotrypsin

Cite this